title: Oxygen inhalation enhances striatal dopamine metabolism and monoamineoxidase enzyme inhibition prevents it: a microdialysis study.
abstract: In order to explore the effect of normobaric oxygen on the extracellular level of dopamine and its metabolites, oxygen (30, 60 and 90%) was administered to freely moving rats after the animals had been pretreated with either monoamineoxidase (MAO)-A and -B inhibitors (0.1 or 1 mg kg(-1) of clorgyline, 1 or 10 mg kg(-1) of selegiline and 75 mg kg(-1) pargyline) or control solution. The levels of dopamine and its metabolites were monitored in microdialysis samples collected every 20 min and directly applied to an on-line high-performance liquid chromatograph combined with electrochemical detection. Normobaric oxygen inhalation decreased the level of extracellular dopamine and increased that of 3,4-dihydroxyphenylacetic acid (DOPAC) in a concentration-dependent manner. These changes were partly prevented by pre-treatment with low doses of selegiline or clorgyline, i.e. by conditions in which monoamineoxidase-A or -B was inhibited. When both isoforms of monoamineoxidase were inhibited, there was a drastic increase in extracellular concentrations of dopamine and 3-methoxytyramine, and the levels of DOPAC and homovanilic acid (HVA) were very low. These results indicate that the intracellular metabolism of cytoplasmic dopamine is enhanced by normobaric hyperoxia in rat striatum.
authors: Department of Anesthesiology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
authors: Y U
authors: YU
authors: Adachi
authors: K
authors: K
authors: Watanabe
authors: H
authors: H
authors: Higuchi
authors: T
authors: T
authors: Satoh
authors: E S
authors: ES
authors: Vizi
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000280:Administration, Inhalation; D000818:Animals; D003010:Clorgyline / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000031:analogs & derivatives* / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006719:Homovanillic Acid / Q000378:metabolism; D018496:Hyperoxia / Q000503:physiopathology; D008297:Male; D017551:Microdialysis; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010100:Oxygen / Q000494:pharmacology*; D010293:Pargyline / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012642:Selegiline / Q000494:pharmacology
chemical_list: D008996:Monoamine Oxidase Inhibitors; D015102:3,4-Dihydroxyphenylacetic Acid; D012642:Selegiline; D010293:Pargyline; D008995:Monoamine Oxidase; C001746:3-methoxytyramine; D003010:Clorgyline; D010100:Oxygen; D004298:Dopamine; D006719:Homovanillic Acid